Abstract:With the rapid clinical development of immune checkpoint inhibitors (ICIs), the standard of care in cancer management has evolved rapidly. However, immunotherapy is not currently beneficial for all patients. In addition to intrinsic tumor factors, other etiologies of resistance to ICIs arise from the complex interplay between cancer and its microenvironment. Recognition of the essential role of the tumor microenvironment (TME) in cancer progression has led to a shift from a tumor-cell-centered view of cancer development, to the concept of a complex tumor ecosystem that supports tumor growth and metastatic dissemination. The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumor cells to escape detection and elimination by the immune system. Regulatory T lymphocytes (Treg), myeloid-derived suppressor cells (MDSCs), and type-2 tumor-associated macrophages (TAM2) are major components of these inhibitory cellular networks, with the ability to suppress innate and adaptive anticancer immunity. They therefore represent major impediments to anticancer therapies, particularly immune-based interventions. Recent work has provided evidence that, beyond their direct cytotoxic effects on cancer cells, several conventional chemotherapeutic (CT) drugs and agents used in targeted therapies (TT) can promote the elimination or inactivation of suppressive immune cells, resulting in enhanced antitumor immunity. In this review, we will analyze findings pertaining to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents (CT and/or TT), and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer strategies, in the era of immunotherapy.

Decoding the Interplay: Exploring Immunotherapy Resistance in the Tumor Microenvironment

Key Players of the Immunosuppressive Tumor Microenvironment and Emerging Therapeutic Strategies

Decoding the Complexity of Immune–Cancer Cell Interactions: Empowering the Future of Cancer Immunotherapy

Cellular Dynamics of Tumor Microenvironment Driving Immunotherapy Resistance in Non-Small-Cell Lung Carcinoma

Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies

Cytokines and soluble mediators as architects of tumor microenvironment reprogramming in cancer therapy

Navigating the Immune Maze: Pioneering Strategies for Un-shackling Cancer Immunotherapy Resistance

Innate Immune Cells in Tumour Microenvironment: A New Frontier in Cancer Immunotherapy

Decoding tumor microenvironment: EMT modulation in breast cancer metastasis and therapeutic resistance, and implications of novel immune checkpoint blockers

Role of tumor microenvironment in cancer progression and therapeutic strategy

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness

Innate immune cells in tumor microenvironment: A new frontier in cancer immunotherapy

Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance

The tumor microenvironment: shaping cancer progression and treatment response

Decoding the Tumour Microenvironment: Molecular Players, Pathways, and Therapeutic Targets in Cancer Treatment

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies

Dissecting the Tumor Microenvironment (TME) to Decipher New Immunotherapy Targets by Using Artificial Intelligence

Modelling the tumor immune microenvironment for precision immunotherapy

Single-Cell Informatics for Tumor Microenvironment and Immunotherapy